“Traffic light” classification to guide latent tuberculosis infection screening prior to starting biologics
| Group | Biologics and targeted therapies |
| Red | Abatacept, adalimumab, alemtuzumab, anakinra, baricitinib, canakinumab, certolizumab pegol, etanercept, golimumab, infliximab, ruxolitinib, tofacitinib |
| Amber | Brodalumab, fingolimod, ixekizumab, sarilumab, secukinumab, tocilizumab, ustekinumab, vedolizumab |
| Green | Afatinib, aflibercept, atezolizumab, axitinib, bevacizumab, blinatumomab, bortezomib, bosutinib, brentuximab vedotin, cabozantinib, carfilzomib, cetuximab, cobimetinib, dabrafenib, daratumumab, dasatinib, eculizumab, elotuzumab, epratuzumab, erlotinib, everolimus, gefitinib, gemtuzumab ozogamicin, ibrutinib, idelalisib, imatinib, inotuzumab, ipilimumab, ixazomib, lapatinib, mepolizumab, natalizumab, nilotinib, nivolumab, ocrelizumab, ofatumumab, omalizumab, panitumumab, pazopanib, pertuzumab, reslizumab, rituximab, sirolimus, temsirolimus, trametinib, trastuzumab, venetoclax |